Recruiting

CPMX3 System

Sponsor:

Compremium AG

Code:

NCT07222826

Conditions

Intracranial Pressure

Intracranial Pressure Changes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CPMX3

Study Details

Brief summary:

Elevated intracranial pressure is a common complication of brain injury which means that the pressure within the skull rises above normal levels. The negative impact of increased intracranial pressure (ICP) on the prognosis of patients has been strongly shown in numerous studies and ICP-based treatment is associated with an important reduction of risk of death. Invasive ICP measurement methods are nowadays a standard of care in severe brain injury. The two available ways of measuring ICP require neurosurgical procedure to implant a catheter and probes within the brain and present risks and complications for the patient, such as infections and intracranial bleeding. In addition, invasive recording of ICP requires neurosurgical expertise and intensive care unit (ICU) facilities, limiting the application of ICP measurements to patients of the acute neuro-ICU (neuro-Intensive Care Unit) with acute brain damage requiring close surveillance to prevent further deterioration of neural tissue and disability. Non-invasive ICP monitoring benefits include no risk of complications seen in invasive monitoring, helping in deciding which patient needs invasive ICP monitoring, and providing ongoing long-term measurements of ICP without having to insert a new device every time. Although many non-invasive ICP measurement methods have been explored, to date, none of them have shown clinical success or usefulness. One under-explored window to ICP is the orbital vein, a small blood vessel located near your eye, which we think could provide a direct link to the intracranial pressure. The study device, called the CPMX3 system, is a non-invasive method to measure pressure in a superficial periorbital vein.

Conditions

Intracranial Pressure

Intracranial Pressure Changes

Study ID

NCT07222826

Start date

Sep 30, 2025

Status verified date

Oct, 2025

Completion date

Sep 30, 2026

Anticipated

Primary completion date

Sep 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Male or female
  • Age > 18
  • Equipped with an invasive ICP monitor as part of standard of care

Exclusion Criteria:

  • Presence of facial and/or skull trauma that could hinder placement of the pneumatic mask or contraindicate ultrasound on the forehead
  • History of recent cranial surgery or hemicraniectomy
  • Active bleeding (proven or suspected)
  • History or known pathological condition or injury linked to the orbital socket influencingvenous outflow (e.g. Grave disease, tumor, inflammation, trauma, glaucoma, etc.)
  • History, or known vein stenosis in ophthalmic veins/cavernous sinus
  • Any other condition that would interfere with measurement technique and routine clinical care according to the judgment of the investigator.

Study Design

Enrollment

15 participants

Anticipated

Intervention Model

Single group

Primary purpose

Other

Interventions and Outcome Measures

Arms

experimental: CPMX3 Measurement

CPMX 3 measurement

Interventions

CPMX3

CPMX3 periorbital vein pressure measurement

Primary outcome measure

  • Safety of venous pressure of the isolated periorbital vein measured with the CPMX3 System to estimate ICP, evaluated by incidence of reported adverse events [ Time Frame: up to 7 days ]
  • Safety of venous pressure of the isolated periorbital vein measured with the CPMX3 System to estimate ICP, evaluated by incidence of reported Device Deficiencies (DDs) [ Time Frame: Up to 7 days ]
  • Safety of venous pressure of the isolated periorbital vein measured with the CPMX3 System to estimate ICP, evaluated by incidence of reported Serious Adverse Device Effects (SADEs) [ Time Frame: Up to 7 Days ]
  • Preliminary accuracy of venous pressure of the isolated periorbital vein measured with the CPMX3 System to estimate ICP, measured in mmHg [ Time Frame: up to 7 days ]

Central Contacts and Locations

Central contacts

Locations

Baylor College of Medicine

Recruiting

Houston, Texas, United States, 77030

More Information

Sponsor

Compremium AG

Last update posted

Oct 30, 2025

Last verified

Oct, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Compremium AG on 2025-10-30.